The company has also included non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized foreign currency activity, impairment on assets and charges related to the exit of facilities (collectively, “non-GAAP net income”), in this press release to provide investors with additional information regarding the company’s financial results.
The company has provided below a reconciliation of non-GAAP operating margin to operating margin and non-GAAP net income to net income, the most directly comparable measures calculated and presented in accordance with GAAP. Non-GAAP operating margins and non-GAAP net income are used by the company’s management and board of directors to understand and evaluate operating performance and trends and provide useful measures for period-to-period comparisons of the company’s business. Accordingly, the company believes that non-GAAP operating margin and non-GAAP net income provide useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors.
Conference Call
The company has scheduled a conference call to discuss its third quarter financial results today, October 27, 2016 at 8:30 a.m. ET. To access the call in the U.S. please dial 877-709-8150. Outside the U.S. please dial 201-689-8354. No participant code is required. A simultaneous webcast of the call will be available via the investor relations section of the Proto Labs website and the following link: http://edge.media-server.com/m/p/o7y5fsbx/lan/en. A replay will be available for 14 days following the call on the investor relations section of Proto Labs’ website.
About Proto Labs, Inc.
Proto Labs is the world’s fastest digital manufacturing source for custom prototypes and low-volume production parts. The technology-enabled company uses advanced 3D printing, CNC machining and injection molding technologies to produce parts within days. The result is an unprecedented speed-to-market value for product designers and engineers worldwide. Visit protolabs.com for more information.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Proto Labs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the “Risk Factors” section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Proto Labs’ future results. The forward-looking statements included in this press release are made only as of the date hereof. Proto Labs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Proto Labs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
Proto Labs, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
(In thousands) | ||||||
September 30, | December 31, | |||||
2016 | 2015 | |||||
(Unaudited) | ||||||
Assets |
||||||
Current assets | ||||||
Cash and cash equivalents | $ | 68,218 | $ | 47,653 | ||
Short-term marketable securities | 39,028 | 33,201 | ||||
Accounts receivable, net | 37,261 | 36,125 | ||||
Inventory | 9,930 | 9,771 | ||||
Income taxes receivable | - | 6,028 | ||||
Other current assets | 5,392 | 5,224 | ||||
Total current assets | 159,829 | 138,002 | ||||
Property and equipment, net | 142,722 | 125,475 | ||||
Long-term marketable securities | 68,387 | 64,789 | ||||
Goodwill | 28,916 | 28,916 | ||||
Other intangible assets, net | 2,817 | 3,337 | ||||
Other long-term assets | 1,374 | 517 | ||||
Total assets | $ | 404,045 | $ | 361,036 | ||
Liabilities and shareholders' equity |
||||||
Current liabilities | ||||||
Accounts payable | $ | 10,703 | $ | 13,643 | ||
Accrued compensation | 10,330 | 9,993 | ||||
Accrued liabilities and other | 3,612 | 2,626 | ||||
Income taxes payable | 541 |
- |
||||
Total current liabilities | 25,186 | 26,262 | ||||
Long-term deferred tax liabilities | 4,247 | 4,240 | ||||
Other long-term liabilities | 3,795 | 2,889 | ||||
Shareholders' equity | 370,817 | 327,645 | ||||
Total liabilities and shareholders' equity |
$ |
404,045 | $ |
361,036 |
||
Proto Labs, Inc. | ||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||
(Unaudited) | ||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||
September 30, | September 30, | |||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||
Revenue | ||||||||||||
Injection Molding (Protomold) | $ | 46,445 | $ | 41,971 | $ | 134,376 | $ | 119,521 | ||||
CNC Machining (Firstcut) | 21,781 | 19,833 | 60,510 | 54,788 | ||||||||
3D Printing (Fineline) | 9,850 | 6,038 | 28,059 | 16,038 | ||||||||
Other | 97 | - | 2,757 | - | ||||||||
Total revenue | 78,173 | 67,842 | 225,702 | 190,347 | ||||||||
Cost of revenue | 33,448 | 27,517 | 99,077 | 77,218 | ||||||||
Gross profit | 44,725 | 40,325 | 126,625 | 113,129 | ||||||||
Operating expenses | ||||||||||||
Marketing and sales | 11,787 | 10,027 | 34,182 | 28,383 | ||||||||
Research and development | 5,976 | 4,760 | 17,110 | 13,471 | ||||||||
General and administrative | 10,020 | 8,134 | 28,397 | 20,683 | ||||||||
Total operating expenses |
27,783 | 22,921 | 79,689 | 62,537 | ||||||||
Income from operations | 16,942 | 17,404 | 46,936 | 50,592 | ||||||||
Other income (expense), net | 625 | 593 | 2,342 | 100 | ||||||||
Income before income taxes | 17,567 | 17,997 | 49,278 | 50,692 | ||||||||
Provision for income taxes | 5,585 | 5,615 | 15,943 | 16,171 | ||||||||
Net income | $ | 11,982 | $ | 12,382 | $ | 33,335 | $ | 34,521 | ||||
Net income per share: | ||||||||||||
Basic |
$ | 0.45 | $ | 0.47 | $ | 1.27 | $ | 1.33 | ||||
Diluted | $ | 0.45 | $ | 0.47 | $ | 1.26 | $ | 1.31 | ||||
Shares used to compute net income per share: | ||||||||||||
Basic | 26,416,041 | 26,083,405 | 26,334,738 | 25,952,451 | ||||||||
Diluted | 26,609,878 | 26,381,313 | 26,539,078 | 26,290,758 | ||||||||
Proto Labs, Inc. | ||||||||
Condensed Consolidated Statements of Cash Flows | ||||||||
(In thousands) | ||||||||
(Unaudited) | ||||||||
Nine Months Ended | ||||||||
September 30, | ||||||||
2016 | 2015 | |||||||
Operating activities | ||||||||
Net income | $ | 33,335 | $ | 34,521 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 12,831 | 10,422 | ||||||
Stock-based compensation expense | 5,260 | 4,515 | ||||||
Deferred taxes | 495 | (310 | ) | |||||
Excess tax benefit from stock-based compensation | (1,965 | ) | (5,212 | ) | ||||
Amortization of held-to-maturity securities | 881 | 936 | ||||||
Loss on impairment of assets | 455 | - | ||||||
Other | (1,381 | ) | - | |||||
Changes in operating assets and liabilities | 6,266 | (3,588 | ) | |||||
Net cash provided by operating activities | 56,177 | 41,284 | ||||||
Investing activities | ||||||||
Purchases of property and equipment | (30,981 | ) | (27,259 | ) | ||||
Purchases of marketable securities | (56,213 | ) | (42,674 | ) | ||||
Proceeds from sales and maturities of marketable securities | 45,907 | 40,899 | ||||||
Net cash used in investing activities | (41,287 | ) | (29,034 | ) | ||||
Financing activities | ||||||||
Payments on debt | - | (107 | ) | |||||
Acquisition-related contingent consideration | (400 | ) | (1,400 | ) | ||||
Proceeds from exercises of stock options and other | 4,168 | 5,165 | ||||||
Excess tax benefit from stock-based compensation | 1,965 | 5,212 | ||||||
Net cash provided by financing activities | 5,733 | 8,870 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (58 | ) | (318 | ) | ||||
Net increase in cash and cash equivalents | 20,565 | 20,802 | ||||||
Cash and cash equivalents, beginning of period | 47,653 | 43,329 | ||||||
Cash and cash equivalents, end of period | $ | 68,218 | $ | 64,131 | ||||
Proto Labs, Inc. | ||||||||||||||||
Reconciliation of GAAP to Non-GAAP Net Income per Share | ||||||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||||||
Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, acquisition costs, impairment on assets and charges related to the exit of facilities |
||||||||||||||||
GAAP net income | $ | 11,982 | $ | 12,382 | $ | 33,335 | $ | 34,521 | ||||||||
Add back: | ||||||||||||||||
Stock-based compensation expense | 1,719 | 1,606 | 5,260 | 4,515 | ||||||||||||
Amortization expense | 163 | 186 | 520 | 559 | ||||||||||||
Impairment on assets | - | - | 455 | - | ||||||||||||
Facilities-related charges | 731 | - | 1,150 | - | ||||||||||||
Acquisition costs | - | 648 | - | 648 | ||||||||||||
Unrealized (gain) loss on foreign currency | (330 | ) | (407 | ) | (1,460 | ) | 211 | |||||||||
Total adjustments 2 | 2,283 | 2,033 | 5,925 | 5,933 | ||||||||||||
Income tax benefits on adjustments 1 | (743 | ) | (708 | ) | (2,054 | ) | (1,851 | ) | ||||||||
Non-GAAP net income | $ | 13,522 | $ | 13,707 | $ | 37,206 | $ | 38,603 | ||||||||
Non-GAAP net income per share: | ||||||||||||||||
Basic | $ | 0.51 | $ | 0.53 | $ | 1.41 | $ | 1.49 | ||||||||
Diluted | $ | 0.51 | $ | 0.52 | $ | 1.40 | $ | 1.47 | ||||||||
Shares used to compute non-GAAP net income per share: | ||||||||||||||||
Basic | 26,416,041 | 26,083,405 | 26,334,738 | 25,952,451 | ||||||||||||
Diluted | 26,609,878 | 26,381,313 | 26,539,078 | 26,290,758 | ||||||||||||
1 For the three months ended September 30, 2016 and 2015, income tax effects were calculated reflecting an effective GAAP tax rate of 31.8% and 31.2%, respectively, and an effective non-GAAP tax rate of 31.9% and 31.6%, respectively. For the nine months ended September 30, 2016 and 2015, income tax effects were calculated reflecting an effective GAAP tax rate of 32.4% and 31.9%, respectively, and an effective non-GAAP tax rate of 32.6% and 31.8%, respectively. The difference between our GAAP and non-GAAP tax rate for the three and nine months ended September 30, 2016 was primarily due to the tax effect of stock-based compensation expense, amortization expense, unrealized gain on foreign currency, impairment on assets and charges related to the exit of facilities. The difference between our GAAP and non-GAAP tax rate for the three and nine months ended September 30, 2015 was primarily due to stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and acquisition costs. | ||||||||||||||||
2 Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, acquisition costs, impairment on assets and charges related to the exit of facilities were included in the following GAAP consolidated statement of operations categories: | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||||||
Cost of revenue | $ | 558 | $ | 136 | $ | 999 | $ | 378 | ||||||||
Marketing and sales | 250 | 288 | 741 | 796 | ||||||||||||
Research and development | 310 | 335 | 1,084 | 964 | ||||||||||||
General and administrative | 1,495 | 1,681 | 4,561 | 3,584 | ||||||||||||
Other income (expense), net | (330 | ) | (407 | ) | (1,460 | ) | 211 | |||||||||
Total adjustments | $ | 2,283 | $ | 2,033 | $ | 5,925 | $ | 5,933 | ||||||||
Proto Labs, Inc. |
||||||||||||
Reconciliation of GAAP to Non-GAAP Operating Margin | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||
September 30, | September 30, | |||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||
Revenue | $ | 78,173 | $ | 67,842 | $ | 225,702 | $ | 190,347 | ||||
Income from operations | 16,942 | 17,404 | 46,936 | 50,592 | ||||||||
GAAP operating margin | 21.7% | 25.7% | 20.8% | 26.6% | ||||||||
Add back: | ||||||||||||
Stock-based compensation expense | 1,719 | 1,606 | 5,260 | 4,515 | ||||||||
Amortization expense | 163 | 186 | 520 | 559 | ||||||||
Impairment on assets | - | - | 455 | - | ||||||||
Facilities-related charges | 731 | - | 1,150 | - | ||||||||
Acquisition costs | - | 648 | - | 648 | ||||||||
Total adjustments | 2,613 | 2,440 | 7,385 | 5,722 | ||||||||
Non-GAAP income from operations adjusted for stock-based compensation expense, amortization expense, impairment on assets, facilities-related charges and acquisition costs |
$ | 19,555 | $ | 19,844 | $ | 54,321 | $ | 56,314 | ||||
Non-GAAP operating margin | 25.0% | 29.3% | 24.1% | 29.6% | ||||||||
Proto Labs, Inc. |
||||||||||||||||||||||||
Comparison of GAAP to Non-GAAP Revenue Growth | ||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||
Three Months Ended | % Change | Nine Months Ended | % Change | |||||||||||||||||||||
September 30, | % | Constant | September 30, | % | Constant | |||||||||||||||||||
2016 |
2015 |
Change | Currencies 1 |
2016 |
2015 |
Change | Currencies 1 | |||||||||||||||||
Revenues | ||||||||||||||||||||||||
United States | $ | 59,574 | $ | 54,408 | 9.5 | % | 9.5 | % | $ | 169,364 | $ | 154,107 | 9.9 | % | 9.9 | % | ||||||||
Europe | 15,610 | 11,297 | 38.2 | % | 44.7 | % | 48,518 | 30,161 | 60.9 | % | 65.7 | % | ||||||||||||
Japan | 2,989 | 2,137 |
39.9 |
% | 17.3 | % | 7,820 | 6,079 | 28.6 | % | 14.8 | % | ||||||||||||
Total Revenue | $ | 78,173 | $ | 67,842 | 15.2 | % | 15.6 | % | $ | 225,702 | $ | 190,347 | 18.6 | % | 18.9 | % | ||||||||
|
||||||||||||||||||||||||
1 Revenue growth for the three- and nine-month periods ended September 30, 2016 has been recalculated using 2015 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. | ||||||||||||||||||||||||
Three Months Ended | % Change | Nine Months Ended | % Change | |||||||||||||||||||||
September 30, |
% |
Constant | September 30, |
% |
Constant | |||||||||||||||||||
2016 |
2015 |
Change 2 |
Currencies 2 |
2016 |
2015 |
Change 2 |
Currencies 2 |
|||||||||||||||||
Revenues | ||||||||||||||||||||||||
United States | $ | 59,574 | $ | 54,408 | 9.5 | % | 9.5 | % | $ | 169,364 | $ | 154,107 | 9.9 | % | 9.9 | % | ||||||||
Europe | 11,629 | 11,297 | 2.9 | % | 9.5 | % | 34,871 | 30,161 | 15.6 | % | 20.4 | % | ||||||||||||
Japan | 2,989 | 2,137 | 39.9 | % | 17.3 | % | 7,820 | 6,079 | 28.6 | % | 14.8 | % | ||||||||||||
Total Revenue | $ | 74,192 | $ | 67,842 | 9.4 | % | 9.7 | % | $ | 212,055 | $ | 190,347 | 11.4 | % | 11.7 | % | ||||||||
2 Revenue growth for the three- and nine-month periods ended September 30, 2016 has been recalculated to exclude revenue earned from our acquisition of Alphaform, and using 2015 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. | ||||||||||||||||||||||||
Proto Labs, Inc. | ||||||||||||
Revenue by Geography - Based on Shipping Location | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||
September 30, | September 30, | |||||||||||
2016 |
2015 |
2016 |
2015 |
|||||||||
Revenues | ||||||||||||
Domestic | ||||||||||||
United States | $ | 55,677 | $ | 50,214 | $ | 158,095 | $ | 144,357 | ||||
International | ||||||||||||
Europe | 15,610 | 11,297 | 48,518 | 30,161 | ||||||||
Japan | 2,989 | 2,137 | 7,820 | 6,079 | ||||||||
United States | 3,897 | 4,194 | 11,269 | 9,750 | ||||||||
Total international | 22,496 | 17,628 | 67,607 | 45,990 | ||||||||
Total revenue | $ | 78,173 | $ | 67,842 | $ | 225,702 | $ | 190,347 | ||||
|
||||||||||||
Proto Labs, Inc. | ||||||||
Product Developer Information | ||||||||
(Unaudited) | ||||||||
Three Months Ended | Nine Months Ended | |||||||
September 30, | September 30, | |||||||
2016 | 2015 | 2016 | 2015 | |||||
Unique product developers and engineers served | 14,271 | 12,541 | 26,528 | 22,633 | ||||
Note: the data above does not include product developers and engineers who purchased products attributable to our acquisition of Alphaform during the periods presented. | ||||||||